Radiotherapy Delivery for Women with Early Breast Cancer
John
Yarnold
Radiotherapy Department, Royal Marsden NHS Foundation Trust and Institute of Cancer
Research, UK
author
text
article
2010
eng
Middle East Journal of Cancer
Shiraz University of Medical Sciences
2008-6709
1
v.
3
no.
2010
105
108
https://mejc.sums.ac.ir/article_41905_98572faf7076f9c1975aae849d600b5c.pdf
Evaluation of Intravenous Magnesium Supplementation as Prophylaxis for Cisplatin-induced Hypomagnesemia
Kazem
Anvari
Department of Radiotherapy and Oncology, Cancer Research Center, Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
author
Mehdi
Sielanian Toussi
Department of Radiotherapy and Oncology, Cancer Research Center, Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
author
Marjaneh
Mirsadraee
Department of Radiotherapy and Oncology, Cancer Research Center, Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
author
text
article
2010
eng
Background: We assessed the effects of cisplatin-based chemotherapy, magnesium supplementation, probable contributory factors such as cisplatin cumulative dose and dose per cycle on serum magnesium levels.Methods: In this prospective randomized study, serum magnesium levels of 59 newly diagnosed adult patients receiving cisplatin-based chemotherapy were studied. The patients were randomly allocated to receive magnesium supplementation at a dose of 5 g IV per cycle (n=31) or to a control group (n=28). Serum magnesium levels <1.8 mg/dL were considered to indicate hypomagnesemia.Results: The decrease in mean magnesium levels with continuing chemotherapy courses was significant in both groups with a more prominent decrease in the control group. In courses 4 and 5, mean magnesium levels were significantly higher among those who received magnesium supplementation than in the control group. Thirty patients (50.8%) had at least one incident of hypomagnesemia after beginning chemotherapy. All hypomagnesemia incidents were mild (mean 1.69, range; 1.52-1.79 mg/dL). Hypomagnesemia was more frequent in the control group (38.7% vs. 60.7%, P=0.09). Although age and sex had no significant effect on the incidence of hypomagnesemia, more hypomagnesemia incidents were observed in patients who received cisplatin in a single loading dose than in those who received the drug in divided doses for each cycle (71.4% % vs. 42.9%, P=0.056).Conclusion: Magnesium supplementation at a dose of 5 g per cycle partially compensated for cisplatin- induced magnesium loss. Monitoring magnesium levels and magnesium supplementation is warranted, especially for those undergoing protracted courses of cisplatin-based chemotherapy. Patients who receive the drug in a single loading dose might be more prone to magnesium loss.
Middle East Journal of Cancer
Shiraz University of Medical Sciences
2008-6709
1
v.
3
no.
2010
109
114
https://mejc.sums.ac.ir/article_41904_ffeed70c399ee57df9e79ae95ecd70c7.pdf
Impact of Scattered Radiation on Testosterone Deficiency and Male Hypogonadism in Rectal Cancer Treated with External Beam Pelvic Irradiation
Niloofar
Ahmadloo
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
author
Farzad
Bidouei
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
author
Mohammad Amin
Mosleh-Shirazi
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
author
Gholam Hossein
Omrani
Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences,
Shiraz, Iran
author
Shapour
Omidvari
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
author
Ahmad
Mosalaei
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
author
Mansour
Ansari
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
author
Halimeh Khatoon
Ahmadi
Radiation Oncology Department, Namazi Hospital, Shiraz, Iran
author
Mohammad
Mohammadianpanah
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
author
text
article
2010
eng
Background: We performed a prospective study to evaluate the effects of pelvic irradiation on FSH, LH and testosterone levels in male patients with rectal adenocarcinoma. Our aim was to compare the level of male sex hormones in peripheral blood serum before and after pelvic irradiation.Methods: The eligible participants were 40 men with rectal adenocarcinoma who underwent pelvic radiotherapy as part of their treatment for primary tumor, either before or after surgery. All patients received a 50-Gy radiation dose to the pelvis, 2 Gy per fraction, five days per week. Blood was sampled three times during the study: once before radiation, at the end of the radiation course and 4 to 6 weeks after radiotherapy.Results: Median age of the patients was 58 years (range 18-82). The mean testis dose of radiation per fraction in all 40 patients was 16.3 cGy with a standard deviation of 15.22 (range 5.5-64.8). Serum levels of FSH revealed a significant increase from 7.5 ± 1.7 IU/L (before treatment) to 20.9 ± 17.8 IU/L [end of radiotherapy (P<0.001)] and 24.1 ± 20.5 IU/L [4 to 6 weeks after radiotherapy (P<0.001)]. Serum LH levels were significantly elevated from 8.04 ± 1.2 IU/L before radiation to 11.6 ± 11.5 IU/L at the end of radiotherapy (P<0.001) and 12.5 ± 9.9 IU/L 4 to 6 weeks after the final course of radiotherapy (P<0.001). There was a decrease in serum testosterone from 5.3±2.1 ng/mL before radiation to 4.2 ± 1.9 ng/mL at the end of radiotherapy (P=0.004) and 4.5 ± 2 ng/mL 4 to 6 weeks after radiotherapy (P=0.035). No significant correlation was seen between age and differences in sex hormones (LH, P=0.605; FSH, P=0.380; testosterone, P=0.161).Conclusion: There was a significant change in serum levels of male sex hormones after pelvic irradiation for rectal cancer (total dose, 50 Gy) that indicates considerable testicular damage under these circumstances. Thus, it seems logical to use techniques that reduce the radiation dose to the testicles and to consider the benefits of hormone replacement therapy as well as semen cryopreservation for high-risk patients who desire children in the future.
Middle East Journal of Cancer
Shiraz University of Medical Sciences
2008-6709
1
v.
3
no.
2010
115
122
https://mejc.sums.ac.ir/article_41908_ac370aae25c9f01b66af20d7b5b342e1.pdf
Calculation of Changes in Radiation Exposure due to Prostate Displacement in Permanent Prostate Brachytherapy
Milad
Baradaran-Ghahfarokhi
Mechanical Engineering Department, School of Engineering, Shiraz University, Shiraz, Iran
author
Mohammad Amin
Mosleh-Shirazi
Physics Unit, Department of Radiotherapy and Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
author
Reza
Faghihi
Mechanical Engineering Department, School of Engineering, Shiraz University, Shiraz, Iran
author
Mohammad Hadi
Bagheri
Department of Radiology and Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
author
Kamal
Hadad
Mechanical Engineering Department, School of Engineering, Shiraz University, Shiraz, Iran
author
Ali
Alavian-Ghavanini
Mechanical Engineering Department, School of Engineering, Shiraz University, Shiraz, Iran
author
Zahra
Siavashpour
Mechanical Engineering Department, School of Engineering, Shiraz University, Shiraz, Iran
author
Hamed
Kasayi
Medical Radiation Engineering Department, School of Engineering, Shahid Beheshti University, Tehran, Iran
author
text
article
2010
eng
Background: Limited studies are available on the calculation of radiation exposure and its associated risks for people in contact with patients who have been treated with permanent prostate brachytherapy. In this study the changes in the radiation exposure were calculated in different stages of the bladder fullness in prostate seed brachytherapy.Methods:Magnetic resonance images of three patients with full and empty bladders and different prostate sizes (32-71 mL; mean 54.6 mL) were used for Monte-Carlo dose calculations. Dose rate to skin for each patient was calculated using MCNP4c, MCNPX.Results: There were no significant differences between dose distribution in the skin relative to the changes in the prostate position due to bladder filling (P=0.05).Conclusion: Our results showed a negligible change in radiation exposure around the patient due to prostate displacement after bladder filling.
Middle East Journal of Cancer
Shiraz University of Medical Sciences
2008-6709
1
v.
3
no.
2010
123
128
https://mejc.sums.ac.ir/article_41909_b130e0c386d9d46c4d014dc0a3ef3d08.pdf
Telomerase Activity in Chicken Embryo Fibroblast Cell Cultures Infected with Marek's Disease Virus
Mohammad
Motamedifar
Department of Bacteriology and Virology, Shiraz HIV/AIDS Research Center (SHARC),
Shiraz University of Medical Sciences, Shiraz, Iran
author
Gregory
Tannock
Department of Applied Biology and Biotechnology, RMIT University, Melbourne, Australia
author
text
article
2010
eng
Background: Telomerase is a ribonucleoprotein, which adds telomeric repeats onto the 3’ end of existing telomers at the end of chromosomes in eukaryotes. One hypothesis states that telomere length may function as a mitotic clock, therefore expression of telomerase activity in cancer cells may be a necessary and essential step for tumor development and progression.Methods: The detectability of telomerase activity in chicken embryo fibroblast (CEF) cells infected with different passages of Marek's disease virus (MDV) was tested with the TRAPEZE® telomerase detection kit at passages 14 (P14), P80/1 and P120 for the Woodland strain, and passage 9 (P9) for the MPF57 strain.Results: The results showed increased telomerase activity in MDV Woodlands strain at P14 and MPF57 strain at P9.Conclusion: Our results suggest that MDV-transformed cells at low passage are a suitable system for the study of telomerases in tumor development and for testing telomerase-inhibiting drugs.
Middle East Journal of Cancer
Shiraz University of Medical Sciences
2008-6709
1
v.
3
no.
2010
129
133
https://mejc.sums.ac.ir/article_41910_5f84fd4f3ae35b8ffd2f094afb829061.pdf
Cutaneous Metastases from Different Internal Malignancies in Egypt
Amen
Zaky
Departments of Medical Oncology, Radiotherapy and Surgical Oncology, South Egypt Cancer Institute, Assuit University, Assuit, Egypt
author
Mostafa
El-Wanis
Departments of Medical Oncology, Radiotherapy and Surgical Oncology, South Egypt Cancer Institute, Assuit University, Assuit, Egypt
author
Hisham
Hamza
Departments of Medical Oncology, Radiotherapy and Surgical Oncology, South Egypt Cancer Institute, Assuit University, Assuit, Egypt
author
Hisham
Abdel-Hafez
Dermatology Department, Faculty of Medicine, Assuit University,Assuit, Egypt
author
Nagwa
Abdel-Azim
Dermatology Department, Faculty of Medicine, Assuit University,Assuit, Egypt
author
text
article
2010
eng
Background: Cutaneous metastasis is defined as the spread of malignant cells from a primary malignancy to the skin. Generally, cutaneous involvement from internal malignancies is uncommon. No reports have focused on the cutaneous metastasis profiles in Egypt or the Middle Eastern population. In this study, we seek to determine the rates at which different internal malignancies give rise to cutaneous metastases upon first diagnosis of the primary tumor.Methods: Patients with internal malignancies who attended the South Egypt Cancer Institute from January 2004 through May 2010 were examined and followed to identify cutaneous metastases, which were confirmed by biopsy and histological evaluation.Results: Among 2208 cases of internal malignancies, 48 cases of cutaneous metastases were detected. The clinical profiles were similar to those from western and Asian countries, although the frequencies of primary tumors differed. Most commonly in Egypt breast cancer and urinary bladder cancers were seen.Conclusion: The risk of skin metastases depends largely on the characteristics of tumor cells, which are similar among different groups.
Middle East Journal of Cancer
Shiraz University of Medical Sciences
2008-6709
1
v.
3
no.
2010
135
139
https://mejc.sums.ac.ir/article_41906_4691acfd8d7afc33d18c2a8044ebef8f.pdf
Synovial Sarcoma of the Palatine Tonsil: Report of Two Cases and Review of the Literature
Bijan
Khademi
Cancer Research Center and Department of Otolaryngology, Shiraz University of Medical
Sciences, Shiraz, Iran
author
Hajar
Bahranifard
Cancer Research Center and Department of Otolaryngology, Shiraz University of Medical
Sciences, Shiraz, Iran
author
Mohammad
Mohammadianpanah
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
author
Mohammad Javad
Ashraf
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
author
Negar
Azarpira
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
author
Mehdi
Dehghani
Department of Hematology Oncology, Shiraz University of Medical Sciences,
Shiraz, Iran
author
text
article
2010
eng
Here, we describe young men with synovial sarcoma in the palatine tonsil, who presented with a 3-4 month history of progressive sore throat, tonsillar ulcerative mass and bleeding. Clinical and radiological examinations revealed that the tumors arose from the palatine tonsil and extended to the parapharyngeal space. Both tumors were too advanced to remove completely; therefore, they underwent surgical debulking during tonsillectomy and partial pharyngectomy. Histopathological and immunohistochem- ical studies confirmed the diagnosis of synovial sarcoma of the palatine tonsil. Despite postoperative radiotherapy and systemic chemotherapy, they relapsed 18 and 22 months later. The first patient died from unresectable local recurrent disease three years after primary diagnosis, and the second patient is alive after 36 months, but suffers from unresectable locoregional recurrent disease and is receiving palliative chemotherapy and supportive care.
Middle East Journal of Cancer
Shiraz University of Medical Sciences
2008-6709
1
v.
3
no.
2010
141
146
https://mejc.sums.ac.ir/article_41903_0419504d45aff8969551b9d80c4f6ad6.pdf
Adult Mesoblastic Nephroma: A Case Report
Mehdi
Salehipour
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
author
Reza
Mohammadian
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
author
Sara
Pakbaz
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
author
Vahid
Emadmarvasti
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
author
Ghasem
Sadeghi
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
author
text
article
2010
eng
Mesoblastic nephroma is a rare entity in adulthood. We report a case of mesoblastic nephroma in a 35-year-old woman who presented with left flank pain. Computed tomography images favored a soft tissue mass in the upper pole of the left kidney. The lesion was excised and sent for pathological analysis. Pathological and immunohisto- chemical studies favored a diagnosis of mesoblastic nephroma.
Middle East Journal of Cancer
Shiraz University of Medical Sciences
2008-6709
1
v.
3
no.
2010
147
150
https://mejc.sums.ac.ir/article_41907_55c854362beeeace4af2f6297192e83a.pdf